academic article

• Lau DKTay RYYeung YHChionh FMooi JMurone CSkrinos EPrice TJMariadason JMTebbutt NC. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.  British Journal of Cancer.  118:966-971. 2018
  Full text if available
• Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Molecular Oncology.  11:1130-1142. 2017
  Full text if available
• Chionh FLau DYeung YPrice TTebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer.  Cochrane Database of Systematic Reviews.  2017:1-218. 2017
  Full text if available
• Parakh SMurphy CLau DCebon JSAndrews MC. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.  Journal of Clinical Pharmacy and Therapeutics.  40:121-123. 2015
  Full text if available
• Lau DKAndrews MCTurner NAzad AADavis IDCebon JS. A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.  Melanoma Research: an international journal of rapid communications of basic and clinical research in melanoma.  24:144-149. 2014
  Full text if available